Pioneering
The Next Generation
of Cancer Treatments
OUR VISION - A WORLD BEYOND CANCER
-Every cancer patient, human or animal, deserves a fighting chance. -
At Metanoi Therapeutics, we aren’t just creating treatments, we’re giving patients and their families hope.
Our Science
About
MD, PhD — Founder and Chief Scientific Officer
Global Leadership in Oncology
Dr. Guilherme Cantuaria is a distinguished physician-scientist and entrepreneur with over two decades of leadership in oncology research and clinical care. Board-certified in both Gynecologic Oncology and Obstetrics and Gynecology in the U.S. and Brazil, Dr. Cantuaria has served as Chairman and Medical Director of the Northside Hospital Cancer Program in Atlanta, GA, since 2011.
Pioneering Roles in Cancer Science
He has held principal investigator roles in major National Cancer Institute (NCI) research programs and has been honored repeatedly as a "Top Doctor" by Castle Connolly and local peer surveys. Dr. Cantuaria is a published author of over 40 peer-reviewed articles and is a recognized authority in cancer biology, clinical trials, and
translational medicine. He holds an MD from the University of Brasilia and completed his residency and fellowship at the University of Miami. He is also the Founder, President, and Chairman of Metano Therapeutics, Inc. and Vetanoi, LLC.
About
Founder, Chief Financial Officer, and Chief Legal Officer
Strategic Expertise in Healthcare & Law
Daniel King is a seasoned business executive and attorney with over 30 years of experience in intellectual property, healthcare operations, and corporate transactions. A former CPA at Price waterhouse Coopers and a former partner at King & amp: Spalding, Mr. King has advised Fortune 500 companies and healthcare practices nationwide. His expertise spans mergers and acquisitions, compliance, technology, and dispute resolution.
Driving Growth Across Healthcare Sectors
In addition to his legal career, he served as CEO of multi- state medical and dental groups. Mr. King has a BBA in Accounting and JD from Georgia State University, where he was Editor of the Law Review. He has also chaired the American Academy of Cosmetic Dentistry Ethics Committee for the past decade.
About
Chief Executive Officer
Driving Innovation from Lab to Market
Stephan Jackman is a dynamic biotechnology executive with broad leadership experience spanning clinical development, operations, and strategic planning. Mr. Jackman also serves as CEO of Alzamend Neuro, where he successfully led the company through an IPO on Nasdaq and raised over $60 million in capital.
He previously held leadership roles at Exit 9 Technologies and Ennaid Therapeutics, managing capital raises, clinical trial operations, and strategic growth initiatives. Mr. Jackman has managed budgets totaling over $100 million and CAPEX/OPEX projects exceeding $500 million.
Cross-Industry Impact from Pharma to Strategy
He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L’Oréal USA, SBM Management Services and Family Intervention Services. He holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.
About
Bradford Sullivan
CAIA, CMT — Chief Operating Officer
and Director of Investor Relations
Capital Markets Expertise for Emerging Biotech
Brad Sullivan brings extensive experience in capital markets, trading, and investor relations to Metanoi Therapeutics. Also Director of Investor Relations at Alzamend Neuro, he led institutional and retail outreach efforts, significantly expanding social media engagement and fund targeting.
Trading Leadership with a Strategic Edge
Mr. Sullivan has over two decades of trading experience at firms including StoneX Group, Russell Investments, and Neonet Securities, where he managed complex equity, FX, and futures transactions across global markets. He is a Chartered Alternative Investment Analyst (CAIA) and a Chartered Market Technician (CMT), and holds a Bachelor of Science in Finance from the University of North Carolina – Wilmington.
